ACT NOW: A Simple Neuropathy Screen Shows Strong Reproducibility #ActAgainstAmputation #Diabetes

Diabetic peripheral neuropathy is common, consequential—and remarkably easy to miss. When sensation fades quietly, an ordinary shoe, an unnoticed blister, or repetitive pressure can become the beginning of a limb-threatening problem.

A practical idea, tested for consistency

ACT—A simple sCreening Tool—combines a brief, patient-administered questionnaire with a simplified clinician sensory examination. Our friends and colleagues across Toronto, Doha, and Manchester have now taken an important next step: testing whether ACT gives consistent results when it is repeated.

Gad and colleagues enrolled 150 adults with type 1 or type 2 diabetes from an outpatient endocrinology clinic. Of these, 126 completed valid baseline and repeat assessments 14 days later using both ACT and the Michigan Neuropathy Screening Instrument (MNSI).

The 14-day results

In plain clinical language, the combined ACT score was stable, and its positive-versus-negative classification showed strong agreement when the test was repeated two weeks later.

ACT questionnaire plus examination (ACT q+e): ICC 0.85
Overall dichotomized ACT classification: κ 0.83
ACT sensory examination components: κ 0.81
Overall reproducibility was comparable with the established MNSI over the same 14-day interval.

What this study does—and does not—show

This is a reproducibility study, not a diagnostic-accuracy study. It establishes that ACT can produce consistent short-interval results. It does not, by itself, establish how accurately ACT identifies neuropathy against objective diagnostic measures.

That distinction matters. Reliability is a necessary rung on the ladder toward a clinically useful screening tool, but it is not the whole ladder. The authors appropriately call for further validation against other established instruments and more objective measures of diabetic peripheral neuropathy. They also note that this was a tertiary-care cohort and that symptoms can fluctuate over time.

The clinical takeaway

A screening tool has to do more than be simple. It has to behave itself when we use it again. These data suggest ACT does exactly that over 14 days, with reproducibility comparable to the MNSI and a format designed for busy and resource-limited clinics.

The next question is diagnostic performance. But this study gives ACT something every scalable screening tool needs first: a strong, reproducible foundation.

Perhaps the best screening test is not the fanciest one. It may be the one that actually gets done—consistently.